Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.

J Vet Intern Med · 2015 · PMC4858101 · PMID 25619518

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significanceP = .06so close (0.05 < p ≤ 0.1)

Overall, more dogs treated with carboplatin experienced some form of gastrointestinal toxicosis (9/35; 26%) than did dogs treated with mitoxantrone (3/38; 8%); however, this difference did not reach statistical significance ( P = .06).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.